Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRT 1419 (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Prelude Therapeutics

    • Most Recent Events

    • 08 May 2023 According to a Prelude Therapeutics media release, data were presented at the 2023 American Association for Cancer Research Annual Meeting.
    • 19 Apr 2023 Results (n=24) presented at the 114th Annual Meeting of the American Association for Cancer Research
    • 15 Mar 2023 According to a Prelude Therapeutics media release, safety data to be presented at AACR 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top